<DOC>
	<DOCNO>NCT01981473</DOCNO>
	<brief_summary>The purpose study examine relationship anti-drug antibody , serum drug concentration , clinical response rheumatoid arthritis patient treat etanercept , adalimumab infliximab .</brief_summary>
	<brief_title>Drug Concentration , Immunogenicity , Efficacy Study Patients With Rheumatoid Arthritis Currently Treated With Etanercept , Adalimumab , Infliximab</brief_title>
	<detailed_description>cross-sectional Population select convenience sampling . Patients sequentially visit rheumatology clinic routine care receive etanercept , adalimumab , infliximab 6 24 month evaluate eligibility interest participation . A maximum 200 patient per treatment enrol .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>1 . Age 18 year old . 2 . Diagnosis RA base 1987 American College Rheumatology revise criterion 3 . Current continuous treatment either etanercept , adalimumab , infliximab minimum 6 month maximum 24 month . 1 . Treatment biosimilar investigational etanercept , adalimumab , infliximab within past 6 month . 2 . Treatment investigational drug within past 3 month five half life drug , whichever longer . 3 . Any medical condition would interfere rheumatoid arthritis evaluation study assessment ( eg , fibromyalgia , lupus ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>rheumatoid arthritis</keyword>
	<keyword>etanercept</keyword>
	<keyword>adalimumab</keyword>
	<keyword>infliximab</keyword>
	<keyword>anti-drug antibody</keyword>
	<keyword>immunogenicity</keyword>
	<keyword>drug concentration</keyword>
</DOC>